No Data
No Data
Tianjin Lisheng Pharmaceutical (002393.SZ): Pharmaceutical Enalapril Indapamide Tab passed the application for market approval.
On July 18th, Gelunhui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) recently received the Drug Registration Certificate (batch numbers: 2024S01619, 2024S01620) for Perindopril and Indapamide tablets (referred to as "the pharmaceutical") with the specifications of Perindopril tert-butylamine 4mg and Indapamide 1.25mg, and Perindopril tert-butylamine 2mg and Indapamide 0.625mg issued by the National Medical Products Administration. The pharmaceutical was approved for listing through a drug marketing license application. Indications for Perindopril and Indapamide tablets: Treatment of primary hypertension in adults. This product is suitable for use alone.
Lisheng Pharmaceutical Gets Nod to Market Doxazosin Mesylate Tablets
China's National Medical Products granted a drug registration certificate to Tianjin Lisheng Pharmaceutical's (SHE:002393) doxazosin mesylate sustained-release tablets, according to the company's
Tianjin Lisheng Pharmaceutical (002393.SZ): Pharmaceutical Duloxetine Hydrochloride Enteric-coated Tablets is approved for listing application.
On July 10th, Gelonhui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) has recently received the Drug Registration Certificate (Approval Number: 2024S01592) from the National Medical Products Administration for the delayed-release tablet of 4mg Doxazosin Mesylate (calculated as C23H25N5O5), which has been granted the marketing authorization. According to the Minet database, the domestic sales of doxazosin mesylate preparations in 2022 and 2023 were 0.579 billion yuan and 638 million yuan, respectively.
Lisheng Pharmaceutical Gets Green Light to Market Indapamide Tablets
Tianjin Lisheng Pharmaceutical's (SHE:002393) indapamide sustained-release tablets obtained marketing approval from China's National Medical Products Administration, according to the company's filing
Tianjin Lisheng Pharmaceutical (002393.SZ): Pharmaceutical Indapamide sustained-release tablets have been approved for marketing.
Tianjin Lisheng Pharmaceutical (002393.SZ) announced that the company has received the approval document issued by the National Medical Products Administration for Inzomelidone sustained-release tablets for the treatment of insomnia.
Lisheng Pharmaceutical Avails of 92-Day Structured Deposit Product
Lisheng Pharmaceutical (SHE:002393) availed of a 92-day, 150 million yuan structured deposit product from China Bohai Bank (HKG:9668), according to a Tuesday filing by parent company Tianjin Developme
No Data